DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has been assigned an average rating of “Moderate Buy” from the twenty-seven ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, twenty-one have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $88.7083.

A number of analysts have recently commented on DXCM shares. Robert W. Baird set a $105.00 target price on DexCom in a research report on Friday, July 31st. UBS Group set a $96.00 price target on DexCom and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Stifel Nicolaus set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a research note on Friday, July 31st. Finally, Canaccord Genuity Group set a $90.00 price objective on DexCom and gave the company a “buy” rating in a report on Monday, August 3rd.

DexCom Price Performance

DXCM stock opened at $87.90 on Monday. The stock has a market cap of $33.17 billion, a P/E ratio of 34.74, a PEG ratio of 1.47 and a beta of 1.42. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom has a twelve month low of $54.11 and a twelve month high of $92.59. The company’s 50 day moving average is $81.24 and its two-hundred day moving average is $72.36.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the firm posted $0.48 EPS. The company’s revenue was up 13.1% on a year-over-year basis. Research analysts expect that DexCom will post 2.64 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at approximately $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Sayer sold 26,756 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 65,777 shares of company stock worth $4,950,714 in the last 90 days. Company insiders own 0.28% of the company’s stock.

Institutional Trading of DexCom

Hedge funds have recently added to or reduced their stakes in the stock. Plato Investment Management Ltd purchased a new stake in shares of DexCom in the second quarter valued at approximately $782,000. BOKF NA grew its holdings in DexCom by 175.7% during the fourth quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock worth $2,344,000 after acquiring an additional 22,505 shares during the period. Aurora Investment Counsel purchased a new position in DexCom in the second quarter worth $2,340,000. Performance Wealth Partners LLC purchased a new position in DexCom in the second quarter worth $1,740,000. Finally, E Fund Management Co. Ltd. acquired a new stake in DexCom in the second quarter valued at $1,273,000. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.